Company pipeline depictions are snapshots that illustrate, at that point in time, where a therapeutic candidate sits in terms of development stage for a specific therapy area or disease. These static views lack the granular detail that informs just how well biopharma have performed year over year, other than noting candidate advances or dropouts. Assessing clinical trial completions provides those details needed to support comparisons of companies’ strategies and performances. This analysis examines the landscape of industry sponsored clinical trials completed in 2016.Trials terminated in this same period are analyzed separately. Similar analyses on trial completions were reported for 2014 and 2015. Snapshot data taken for 2015 and 2016 were nearly identical with respect to the date when data was exported: February 11, 2016 (3028 completed trials) and February 13, 2017 (3420 completed trials), respectively. Oncology trial completions dominated the landscape with 826 trials, but at the disease level, Type 2 diabetes took top spot with 190 completed trials. For terminated trials, in 2015 there were 459 trials and in 2016, 603 trials were terminated. Oncology topped 2016 trial terminations, and 53 of these trials focused on non small cell lung cancer (NSCLC).